2022
Role of skin autofluorescence in managing renal and cardiac diseases in outpatient dermatology
Etaee F, Naguib T, Goldust M, Daveluy S, Maibach H. Role of skin autofluorescence in managing renal and cardiac diseases in outpatient dermatology. Skin Research And Technology 2022, 28: 889-905. PMID: 36305176, PMCID: PMC9907660, DOI: 10.1111/srt.13211.Peer-Reviewed Original ResearchConceptsChronic kidney diseaseCardiac diseaseManagement of CKDTissue advanced glycation end productsGlycation end productsCardiovascular eventsCKD patientsCause mortalitySubclinical atherosclerosisCardiovascular mortalityArterial stiffnessIndependent predictorsPeritoneal dialysisSAF measurementVascular damageKidney diseaseSAF levelsInflammatory diseasesSkin autofluorescenceOutpatient dermatologyVegetarian dietSkin resultsLiterature searchDiseaseGoogle Scholar
2021
Differences Between Patients With Intermittent Claudication and Critical Limb Ischemia Undergoing Endovascular Intervention: Insights From the Excellence in Peripheral Artery Disease Registry
Patel K, Liu Y, Etaee F, Patel C, Monteleone P, Patel M, Alaiti M, Metzger C, Banerjee A, Minniefield N, Tejani I, Brilakis E, Shishehbor M, Banerjee S. Differences Between Patients With Intermittent Claudication and Critical Limb Ischemia Undergoing Endovascular Intervention: Insights From the Excellence in Peripheral Artery Disease Registry. Circulation Cardiovascular Interventions 2021, 14: e010635. PMID: 34706553, DOI: 10.1161/circinterventions.121.010635.Peer-Reviewed Original ResearchConceptsCritical limb ischemiaPeripheral Artery Disease (XLPAD) registryIntermittent claudicationPeripheral artery diseaseArtery diseaseEndovascular interventionDisease RegistryMajor adverse limb event ratesMajor adverse limb eventsMultilevel peripheral artery diseaseAdverse limb eventsAdverse limb outcomesOptimal medical therapyTarget limb revascularizationBaseline risk factorsChronic kidney diseaseEndovascular revascularization strategiesFemoropopliteal artery interventionAngiographic distributionCause mortalityEndovascular revascularizationLimb revascularizationMultivariable adjustmentLimb ischemiaLimb outcomes
2020
CHA2DS2-VASc and readmission with new-onset atrial fibrillation, atrial flutter, or acute cerebrovascular accident
Rutland J, Ayoub K, Etaee F, Ogunbayo G, Darrat Y, Marji M, Masri A, Elayi C. CHA2DS2-VASc and readmission with new-onset atrial fibrillation, atrial flutter, or acute cerebrovascular accident. International Journal Of Cardiology 2020, 323: 72-76. PMID: 32800906, DOI: 10.1016/j.ijcard.2020.08.027.Peer-Reviewed Original ResearchConceptsAF/atrial flutterAcute cerebrovascular accidentCerebrovascular accidentAtrial flutterAtrial fibrillationIndex hospitalizationAtrial arrhythmiasNew-onset atrial fibrillationOverall re-admission rateNew-onset atrial arrhythmiasPrior atrial arrhythmiaLarge contemporary cohortNationwide Readmissions DatabaseRe-admission ratesMonths of hospitalizationVASc risk scoreCHA2DS2-VAScCause mortalityReadmission ratesSecondary outcomesHospital readmissionHospitalized patientsPrimary outcomeContemporary cohortStudy cohortDigoxin, mortality, and cardiac hospitalizations in patients with atrial fibrillation and heart failure with reduced ejection fraction and atrial fibrillation: An AF-CHF analysis
Elayi C, Shohoudi A, Moodie E, Etaee F, Guglin M, Roy D, Khairy P, Investigators A. Digoxin, mortality, and cardiac hospitalizations in patients with atrial fibrillation and heart failure with reduced ejection fraction and atrial fibrillation: An AF-CHF analysis. International Journal Of Cardiology 2020, 313: 48-54. PMID: 32320783, DOI: 10.1016/j.ijcard.2020.04.047.Peer-Reviewed Original ResearchConceptsReduced ejection fractionAtrial fibrillationCardiovascular hospitalizationEjection fractionImpact of digoxinArrhythmic deathHazard ratioHeart failureCongestive Heart Failure trialAF-CHF trialsHeart Failure TrialSafety of digoxinSubgroup of patientsMarginal structural modelingCardiovascular causesCause mortalityCardiac hospitalizationSecondary outcomesFailure TrialClinical benefitHospitalizationPatientsDigoxinFibrillationOne-year